{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Pancreatic+Adenocarcinoma&page=20",
    "query": {
      "condition": "Advanced Pancreatic Adenocarcinoma",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 557,
    "total_pages": 56,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Pancreatic+Adenocarcinoma&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Pancreatic+Adenocarcinoma&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T13:40:48.544Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07223047",
      "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Malignancies",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Colorectal Cancer (CRC)",
        "Pancreatic Ductal Adenocarcinoma (PDAC)"
      ],
      "interventions": [
        {
          "name": "BMS-986523",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 252,
      "start_date": "2025-11-25",
      "completion_date": "2028-10-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-10-15T13:40:48.544Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • San Antonio, Texas • West Valley City, Utah + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "West Valley City",
          "state": "Utah"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07223047"
    },
    {
      "nct_id": "NCT05877599",
      "title": "A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Colorectal Carcinoma",
        "Pancreatic Adenocarcinoma",
        "Breast Cancer",
        "Other Solid Tumors",
        "Ovarian Cancer",
        "Myeloid Neoplasms (AML/MDS)"
      ],
      "interventions": [
        {
          "name": "NT-175",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2023-07-12",
      "completion_date": "2029-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-15T13:40:48.544Z",
      "location_count": 20,
      "location_summary": "Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05877599"
    },
    {
      "nct_id": "NCT06907043",
      "title": "A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "EIK1004-001 (IMP1707-001)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eikon Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 130,
      "start_date": "2025-04-30",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-19",
      "last_synced_at": "2026-10-15T13:40:48.544Z",
      "location_count": 6,
      "location_summary": "Denver, Colorado • Lake Mary, Florida • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06907043"
    },
    {
      "nct_id": "NCT00585078",
      "title": "Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2004-05",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2017-04-10",
      "last_synced_at": "2026-10-15T13:40:48.544Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00585078"
    },
    {
      "nct_id": "NCT00470535",
      "title": "Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 18,
      "start_date": "2007-01",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2017-02-23",
      "last_synced_at": "2026-10-15T13:40:48.544Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00470535"
    },
    {
      "nct_id": "NCT07360314",
      "title": "Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "M7437",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2026-02-13",
      "completion_date": "2029-03-28",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-15T13:40:48.544Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Huntersville, North Carolina • Galveston, Texas + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "Galveston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07360314"
    },
    {
      "nct_id": "NCT02333188",
      "title": "Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adenocarcinoma of Unknown Primary",
        "Adult Cholangiocarcinoma",
        "Gallbladder Carcinoma",
        "Gastric Adenocarcinoma",
        "Malignant Gastrointestinal Neoplasm",
        "Metastatic Pancreatic Adenocarcinoma",
        "Pancreatic Adenocarcinoma",
        "Stage III Ampulla of Vater Cancer",
        "Stage III Pancreatic Cancer",
        "Stage IIIA Gallbladder Cancer",
        "Stage IIIA Gastric Cancer",
        "Stage IIIB Gallbladder Cancer",
        "Stage IIIB Gastric Cancer",
        "Stage IV Ampulla of Vater Cancer",
        "Stage IV Gallbladder Cancer",
        "Stage IV Gastric Cancer",
        "Stage IV Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2014-12",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2023-05-31",
      "last_synced_at": "2026-10-15T13:40:48.544Z",
      "location_count": 8,
      "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02333188"
    },
    {
      "nct_id": "NCT05969860",
      "title": "At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Anal Carcinoma",
        "Advanced Biliary Tract Carcinoma",
        "Advanced Bladder Carcinoma",
        "Advanced Breast Carcinoma",
        "Advanced Carcinoid Tumor",
        "Advanced Cervical Carcinoma",
        "Advanced Colorectal Carcinoma",
        "Advanced Gastric Carcinoma",
        "Advanced Glioblastoma",
        "Advanced Head and Neck Carcinoma",
        "Advanced HER2 Positive Breast Carcinoma",
        "Advanced Lung Carcinoma",
        "Advanced Lung Small Cell Carcinoma",
        "Advanced Malignant Germ Cell Tumor",
        "Advanced Malignant Solid Neoplasm",
        "Advanced Neuroendocrine Carcinoma",
        "Advanced Ovarian Carcinoma",
        "Advanced Pancreatic Carcinoma",
        "Advanced Prostate Small Cell Neuroendocrine Carcinoma",
        "Advanced Prostate Carcinoma",
        "Hematopoietic and Lymphoid System Neoplasm",
        "Multiple Myeloma",
        "Myelodysplastic Syndrome",
        "Advanced Basal Cell Carcinoma",
        "Advanced Cholangiocarcinoma",
        "Advanced Endometrial Carcinoma",
        "Advanced Esophageal Carcinoma",
        "Advanced Fallopian Tube Carcinoma",
        "Advanced Hepatocellular Carcinoma",
        "Advanced Liver Carcinoma",
        "Advanced Lymphoma",
        "Advanced Malignant Testicular Neoplasm",
        "Advanced Melanoma",
        "Advanced Merkel Cell Carcinoma",
        "Advanced Penile Carcinoma",
        "Advanced Primary Malignant Central Nervous System Neoplasm",
        "Advanced Renal Cell Carcinoma",
        "Advanced Sarcoma",
        "Advanced Skin Squamous Cell Carcinoma",
        "Advanced Urethral Carcinoma",
        "Advanced Vaginal Carcinoma",
        "Advanced Vulvar Carcinoma",
        "Advanced Appendix Carcinoma",
        "Advanced Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Clinical Encounter",
          "type": "PROCEDURE"
        },
        {
          "name": "Home Health Encounter",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2023-08-23",
      "completion_date": "2027-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-10-15T13:40:48.544Z",
      "location_count": 2,
      "location_summary": "Jacksonville, Florida • Grand Forks, North Dakota",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Grand Forks",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05969860"
    },
    {
      "nct_id": "NCT06818812",
      "title": "A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "INCB186748",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "GEMNabP",
          "type": "DRUG"
        },
        {
          "name": "mFOLFIRINOX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-03-27",
      "completion_date": "2027-03-27",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-15T13:40:48.544Z",
      "location_count": 9,
      "location_summary": "Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 6 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06818812"
    },
    {
      "nct_id": "NCT04895709",
      "title": "A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cervical Cancer",
        "Gastric/Gastroesophageal Junction Adenocarcinoma",
        "Microsatellite Stable Colorectal Cancer",
        "Non-Small-Cell Lung Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Carcinoma, Renal Cell",
        "Urothelial Carcinoma",
        "Pancreatic Adenocarcinoma",
        "Melanoma",
        "Ovarian Neoplasms",
        "Triple Negative Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "BMS-986340",
          "type": "DRUG"
        },
        {
          "name": "BMS-936558-01",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Pumitamig",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1109,
      "start_date": "2021-05-27",
      "completion_date": "2031-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-10-15T13:40:48.544Z",
      "location_count": 11,
      "location_summary": "Clovis, California • Los Angeles, California • Newport Beach, California + 6 more",
      "locations": [
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04895709"
    }
  ]
}